| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $401K | — | — |
| Cost of Revenue | $370K | — | — |
| R&D Expense | $12.6M | — | +22.1% |
| SG&A Expense | $6.6M | — | -14.7% |
| Operating Income | -$19.1M | — | -6.1% |
| Net Income | -$18.6M | — | -10.6% |
| EPS (Basic) | -$0.27 | — | -8.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $68.3M | -15.4% | -42.7% |
| Accounts Receivable | $157K | -42.7% | — |
| Inventory | $206K | +51.5% | +586.7% |
| Current Assets | $71.1M | -14.7% | -41.2% |
| Total Assets | $81.6M | -13.7% | -38.8% |
| Current Liabilities | $9.8M | +23.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.6M | — | -7.9% |
| Capital Expenditures | $33K | — | -26.7% |
| Investing Cash Flow | -$33K | — | +26.7% |
| Financing Cash Flow | $2.2M | — | -85.1% |
| Free Cash Flow | -$14.6M | — | -7.8% |
| +26.2% |
| Total Liabilities | $15.3M | +10.4% | +2.6% |
| Stockholders' Equity | $66.3M | -17.8% | -44.0% |